AstraZeneca’s Mystic OS analysis paints tremelimumab as a dud in NSCLC

AstraZeneca’s Mystic OS analysis paints tremelimumab as a dud in NSCLC

Submitted by admin on November 16, 2018 - 12:19pm
Source: 
Fierce Biotech
News Tags: 
AstraZeneca
clinical trials
tremelimumab
non-small cell lung cancer
Headline: 
AstraZeneca’s Mystic OS analysis paints tremelimumab as a dud in NSCLC
snippet: 

Overall survival data from AstraZeneca’s phase 3 Mystic trial have cast more doubts on the prospects of anti-CTLA4 antibody tremelimumab. 

Do Not Allow Advertisers to Use My Personal information